isoxsuprine

Small moleculeexperimental

Isoxsuprine (used as isoxsuprine hydrochloride) is a drug used as a vasodilator in humans (under the trade name Duvadilan) and equines. Isoxsuprine is a β2 adrenoreceptor agonist that causes direct relaxation of uterine and vascular smooth muscle via β2 receptors. Isoxsuprine it is used in humans for treatment of premature labor, i.e. a tocolytic, and as a vasodilator for the treatment of cerebral vascular insufficiency, Raynaud's phenomenon, and other conditions. Isoxsuprine may increase the heart rate, cause changes in blood pressure, and irritate the GI tract. It should, therefore, be used with caution if combined with other drugs that affect blood pressure, such as sedatives and anesthetic drugs. Isoxsuprine is most commonly used to treat hoof-related problems in the horse, most commonly for laminitis and navicular disease, as its effects as a vasodilator are thought to increase circulation within the hoof to help counteract the problems associated with these conditions. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Feb 15, 2019 (NCT03752307)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1
Mol. weight
301.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • defencin
  • dilavase
  • duvadilan
  • duvadilan
  • duvadilan
  • duvadilan
  • duvadilan
  • duvadilan
  • duvadilan ret
  • isoxsuprine
  • isoxsuprine
  • isoxsuprine
  • isoxsuprine
  • isoxsuprine
  • isoxsuprine
  • isoxsuprine
  • isoxsuprine
  • isoxsuprine hcl
  • isoxsuprine hcl
  • isoxsuprine hcl
  • isoxsuprine hydrochloride
  • isoxuprine
  • (r/s) isoxsuprine hydrochloride
  • vadosilan
  • vasodilan
  • vasodilan

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03752307Phase 1/Phase 2 (Phase 2)Feb 15, 2019University of New Mexico
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of New MexicoAcademic/Hospital1112019
1 organizations
Page 1 / 1